Sign In
Buy CSLLY
$57.96
-0.88 (-1.50%)
At Close: Nov 17, 2025
Carlisle: Mixed Q3, Undervalued Ahead Of Policy Easing
09:45am, Wednesday, 05'th Nov 2025
Carlisle Companies remains a Buy, with a target price lowered to $358 (10% upside) due to more conservative financial assumptions. CSL's Q3 results were mixed, with stable revenue supported by acquis
CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript
11:46pm, Tuesday, 04'th Nov 2025
CSL Limited (OTCQX:CSLLY) Analyst/Investor Day November 4, 2025 6:00 PM EST Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Paul McKenzie - MD, CEO & Executive Direc
Carlisle Companies Incorporated (NYSE:CSL) Given Consensus Rating of “Hold” by Brokerages
01:52am, Thursday, 30'th Oct 2025
Carlisle Companies Incorporated (NYSE: CSL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the stock, MarketBeat reports. One rese
Asset Management One Co. Ltd. Sells 673 Shares of Carlisle Companies Incorporated $CSL
04:09am, Wednesday, 29'th Oct 2025
Asset Management One Co. Ltd. trimmed its position in Carlisle Companies Incorporated (NYSE: CSL) by 3.7% during the second quarter, according to its most recent 13F filing with the Securities and Exc
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
04:57am, Tuesday, 28'th Oct 2025
CSL Limited (OTCQX:CSLLY) Shareholder/Analyst Call October 27, 2025 7:01 PM EDT Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Brian McNamee Paul McKenzie - MD, CEO
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA , Oct. 26
Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based quadrivalent vaccines (QIVe) in the pr
597 Shares in Carlisle Companies Incorporated $CSL Purchased by Blair William & Co. IL
06:11am, Sunday, 19'th Oct 2025
Blair William and Co. IL purchased a new stake in Carlisle Companies Incorporated (NYSE: CSL) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund pu
Carlisle Companies Incorporated $CSL Shares Sold by IFP Advisors Inc
06:10am, Sunday, 19'th Oct 2025
IFP Advisors Inc lessened its holdings in shares of Carlisle Companies Incorporated (NYSE: CSL) by 29.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institu
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
UCLOUDLINK's Groundbreaking PetPhone Launches on HKT's CSL Network in Hong Kong
08:29am, Friday, 26'th Sep 2025
HONG KONG , Sept. 26, 2025 /PRNewswire/ -- UCLOUDLINK GROUP INC.
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
07:00am, Friday, 26'th Sep 2025
SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guideline
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
02:30am, Friday, 26'th Sep 2025
FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO , Sept.
CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript
01:37am, Tuesday, 19'th Aug 2025
CSL Limited (OTCQX:CSLLY) Q4 2025 Earnings Conference Call August 18, 2025 8:00 PM ET Company Participants Andy Schmeltz - Executive Vice President of CSL Behring Chris Cooper - Head of Investor Relat
Australian biopharma firm CSL posts 14% rise in annual profit
05:54pm, Monday, 18'th Aug 2025
Australian biopharmaceutical company CSL reported 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring.
